|

Changes in Person-reported Outcomes and Behavior Using the Accu-Chek SmartGuide CGM and Predict App

RECRUITINGN/ASponsored by FIDAM RDC
Actively Recruiting
PhaseN/A
SponsorFIDAM RDC
Started2026-02-01
Est. completion2026-10-31
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

The goal of this controlled pre-post-trial is to test the Accu-Chek SmartGuide continuous glucose monitoring (CGM) system and whether its predictive features provide additional benefits for adults with type 1 diabetes or insulin- treated type 2 diabetes. The main questions this study aims to answer are: * Does using the Accu-Chek SmartGuide together with the Predict App change participants' fear of hypoglycemia? * Does the Predict App affect other psychological and behavioral outcomes, such as sleep quality, confidence in preventing hypoglycemia, diabetes- related distress, and diabetes empowerment? * Does the use of the predictive features affect glucose levels and the way participants use and respond to CGM alarms and trend information? Participants will use the Accu-Chek SmartGuide for 6 weeks. During the first 2 weeks, participants will use the CGM system without the predictive features. During the following 4 weeks, participants will use the system together with the Accu-Chek SmartGuide Predict App. Participants will complete online questionnaires at two time points (after 2 and after 6 weeks) and answer short questions twice a day through a smartphone app during the first 2 weeks and the last 2 weeks of the study. CGM data will be collected throughout the study. A subgroup of 10 participants will also be invited to take part in an online interview about their experiences with the predictive features.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Type 1 diabetes or Type 2 diabetes with intensified insulin therapy (defined as basal-bolus therapy with self-adjustment of bolus doses)
* CGM use during the past 3 months (without predictive features)
* Age ≥ 18 years
* HbA1c \< 10%
* Informed consent

Exclusion Criteria:

* Use of the SmartGuide CGM solution
* AID use
* Current treatment with psychiatric medications
* Diabetes duration \< 3 months
* Current or planned pregnancy
* Peripheral neuropathy that will impact sleep quality according to the judgement of the participant
* Severe complications (e.g. kidney disease, cancer)

Conditions15

Continuous Glucose Monitoring SystemDiabetesDiabetes (DM)Diabetes DistressDiabetes MellitusDiabetes Mellitus ( Type 1 and Type 2)Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Ecological Momentary AssessmentFear of Hypoglycemia

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.